11-Nov-2022 | Facts and Factors
According to Facts and Factors, the global cervical dysplasia market size was estimated to be worth roughly USD 584.86 million in 2021 and is predicted to grow to around USD 974.11 million by 2028. The global cervical dysplasia market is predicted to grow at a CAGR of roughly 7.56% during the forecast period.
The rise in publicly supported cancer screening programs is one of the key factors driving the global cervical dysplasia market. For instance, Public Health England launched the first government campaign to increase awareness of cervical dysplasia screening using smear tests in March 2019. The percentage of women aged 25 and older who receive smear tests is currently at its lowest point in two decades, according to the same source, as a result of the stigma and dread associated with the Pap test.
Browse the full “Cervical Dysplasia Market Size, Share, Growth Analysis Report By Diagnosis Type (Diagnostic Tests, Diagnostic Devices), By End Use (Hospitals, Diagnostic Centers, Ambulatory Surgical Centers), and By Region - Global and Regional Industry Insights, Overview, Comprehensive Analysis, Trends, Statistical Research, Market Intelligence, Historical Data and Forecast 2022 – 2028" report at https://www.fnfresearch.com/cervical-dysplasia-market
Around 71.4% of women were screened in March 2018, according to data from NHS Digital. PHE recently started a campaign to spread awareness across several platforms in England by collaborating with major media outlets and a number of social media platforms. Thus, a rise in the number of initiatives undertaken by the government to enhance the screening of cervical dysplasia is expected to boost market growth in the near future.
Growing efforts to raise awareness of the condition by the governments of various nations are anticipated to help the market in the future. Hospitals have also adopted a number of initiatives, which is projected to increase the market size throughout the forecast period. Other significant drivers shaping the global cervical dysplasia market include the availability of technologically improved diagnostic tools and growing healthcare infrastructure. The year 2017 saw the launch of the "Smear your Mea" New Zealand Health campaign. The program attempts to encourage women to obtain smear tests and to stop the spread of cancer. Another significant factor driving the market's development is the expansion of hospital alliances. B.C. Women's Hospital and Health Centre, an organization under the Provincial Health Services Authority, established cooperation with Surrey's many family doctors and other communities in May 2019 to reach out to women who find regular screening of the disease difficult. Such elements are probably going to help industry growth during the assessment period.
The global cervical dysplasia market as well as the global healthcare systems have both been significantly impacted by the COVID-19 pandemic. According to a report in Cancer Connect 2020, researchers from the Dana Farber Cancer Institute discovered that during the COVID-19 pandemic, diagnoses of the six most common cancer types—breast, colorectal, lung, pancreatic, gastric, and esophageal cancers—declined by 46%. The Centers for Disease Control and Prevention (CDC) and numerous other medical professional organizations also recommended delaying elective surgeries, cancer screenings, and other health prevention services unless the risks outweighed the benefits and preparing the hospital infrastructure for the care of COVID-19 patients.
The global cervical dysplasia market is segmented based on type, end-user, and region.
Based on type, the market is segmented into diagnostic tests and diagnostics devices. Cervical dysplasia diagnostic tests controlled the market. This is because of its effectiveness, adaptability, reimbursement procedures, and economic efficiency. These tests have a better penetration in low- and middle-income nations as a result of their cost-effectiveness.
Based on end-user, the market is segmented into hospitals, Diagnostic Centers, and Ambulatory Surgical Centers. Cervical dysplasia was mostly sold by hospitals. This is because there are numerous payment plans and technologically sophisticated diagnostic tools and tests available. Additionally, advancing medical infrastructure has made it possible for hospitals to outfit various technologically sophisticated diagnostic devices, boosting both diagnostic effectiveness and overall patient happiness.
In 2021, North America dominated the global cervical dysplasia market and generated the biggest revenue share. Throughout the projection period, it is anticipated that the region would keep its position. The region's cervical dysplasia market is expected to be driven by factors including technological advancements, an increase in the prevalence of various associated diseases, rising awareness and screening programs, and supportive initiatives by public and private organizations to increase the adoption of HPV testing.
Report Scope
Report Attribute |
Details |
Market Size in 2021 |
USD 584.86 Million |
Projected Market Size in 2028 |
USD 974.11 Million |
CAGR Growth Rate |
7.56% CAGR |
Base Year |
2021 |
Forecast Years |
2022-2028 |
Key Market Players |
Qiagen N.V.; Quest Diagnostics; Abbott Laboratories; Hologic Inc.; Karl Kaps GmbH & Co. KG; DYSIS Medical Ltd.; CooperSurgical Inc.; Micromedic Technologies Ltd.; OncoHealth Corporation Inc.; BD; Roche., and others. |
Key Segment |
By Diagnosis Type, End Use, and Region |
Major Regions Covered |
North America, Europe, Asia Pacific, Latin America, and the Middle East &, Africa |
Purchase Options |
Request customized purchase options to meet your research needs. Explore purchase options |
List of prominent players in the global cervical dysplasia market:
- Qiagen N.V.
- Quest Diagnostics
- Abbott Laboratories
- Hologic, Inc.
- Karl Kaps GmbH & Co. KG
- DYSIS Medical Ltd.
- CooperSurgical Inc.
- Micromedic Technologies Ltd.
- OncoHealth Corporation, Inc.
- BD
- Roche
- Others
Recent Developments:
In June 2022, F. Hoffmann-La Roche Ltd, a Swiss multinational healthcare company, announced the official launch of a ‘human papillomavirus (HPV) self-sampling solution’ in the regions accepting the CE mark. This test kit mainly helps in screening for HPV, which can detect women who are at risk of developing cervical cancer.
In January 2022, SANSURE BIOTECH INC., an in-vitro diagnostic products supplier, announced that its ‘HPV DNA Diagnostic Kit (HPV 13+2)’ was approved by the China National Medical Products Administration (NMPA). The kit is developed with advanced magnetic beads technology and above 13 kinds of high-risk genotypes to assure that the kit is capable of cervical cancer screening.
The global cervical dysplasia market is segmented as follows:
By Diagnosis Type
- Diagnostic Tests
- Diagnostic Devices
By End Use
- Hospitals
- Diagnostic Centers
- Ambulatory Surgical Centers
By Region
- North America
- Europe
- France
- The UK
- Spain
- Germany
- Italy
- Nordic Countries
- Benelux Union
- Belgium
- The Netherlands
- Luxembourg
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- Southeast Asia
- Indonesia
- Thailand
- Malaysia
- Singapore
- Rest of Southeast Asia
- Rest of Asia Pacific
- The Middle East & Africa
- Saudi Arabia
- UAE
- Egypt
- South Africa
- Rest of the Middle East & Africa
- Latin America
- Brazil
- Argentina
- Rest of Latin America
About Us:
Facts & Factors is a leading market research organization offering industry expertise and scrupulous consulting services to clients for their business development. The reports and services offered by Facts and Factors are used by prestigious academic institutions, start-ups, and companies globally to measure and understand the changing international and regional business backgrounds. Our client’s/customer’s conviction on our solutions and services has pushed us in delivering always the best. Our advanced research solutions have helped them in appropriate decision-making and guidance for strategies to expand their business.
Contact Us:
Facts & Factors
A 2108, Sargam,
Nanded City,
Sinhagad Road,
Pune 411041, India
USA: +1-347-989-3985
Email: [email protected]
Web: https://www.fnfresearch.com
